Clinical Trials Directory
We are doing this study to find out if an experimental drug called ADX-2191 (the study drug) is a safe and effective option for people with retinitis pigmentosa (RP) due to confirmed rhodopsin mutations.
We are doing this study to find out if certain experimental drug combinations are safe and effective options for people who have recurrent or persistent endometrial cancer (cancer that has come back after treatment or does not respond to treatment).
We are doing this study to find out if carefully watching patients with low risk germ cell tumors after surgery will have different results than treating people with chemotherapy afer their surgery. For people who are in standard risk groups related to germ cell tumors, we want to compare the effects of carboplatin with cisplatin and find out which of these drugs seems to work better.
We are doing this study to find out if an experimental drug called efruxifermin (EFX) is a safe and effective option for people who have nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis (scarring of the liver tissue).
We are doing this study to help us identify the underlying causes of brain disorders such as delirium and/or dementia.
We are doing this study to find out if a new experimental drug called NVL-655 (the study drug) is a beneficial option for people with NSCLC.
We are doing this study to find out if a medical technology called the Signatera blood test can help doctors and patients determine the best course of treatment for bladder cancer after the patient has a radical cystectomy (removal of the bladder and surrounding lymph nodes). The Signatera test is used to detect cancer DNA in the blood before cancer can be seen using imaging (like MRI or CT scans).
We are doing this study to find out if an investigational gene therapy drug called ABBV-RGX-314 (the study drug) is a safe and effective option for people with diabetic retinopathy. The study drug is delivered directly into the suprachoroidal space of the eye using a technology called Microinjector®, which is an experimental needle device.